Cited by 113vaccines and immunoinformatics approachesImmune responses and vaccinationsSARS-CoV-2 and COVID-19 Research

The DOI matches its Crossref record; 221 of the 222 references it cites were found in a registry or an index.

Current Challenges in Vaccinology

Open access

Kennedy, Richard B., Ovsyannikova, Inna G., Palese, Peter, Poland, Gregory A.·2020·Frontiers in Immunology

DOI 10.3389/fimmu.2020.01181PMC PMC7329983

Open this paper in CoChat — free account Open PDF

Abstract

The development of vaccines, which prime the immune system to respond to future infections, has led to global declines in morbidity and mortality from dreadful infectious communicable diseases. However, many pathogens of public health importance are highly complex and/or rapidly evolving, posing unique challenges to vaccine development. Several of these challenges include an incomplete understanding of how immunity develops, host and pathogen genetic variability, and an increased societal skepticism regarding vaccine safety. In particular, new high-dimensional omics technologies, aided by bioinformatics, are driving new vaccine development (vaccinomics). Informed by recent insights into pathogen biology, host genetic diversity, and immunology, the increasing use of genomic approaches is leading to new models and understanding of host immune system responses that may provide solutions in the rapid development of novel vaccine candidates.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3389/fimmu.2020.01181

Cites

221 of 221 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Barriers to vaccine development. Vaccines are the most effective public health tool for controlling infectious diseases. Despite considerable success, there is room for improvement in many current vaccines and there are a large number of new and re-emerging pathogens for which we do not have effective vaccines. Vaccine development faces a number of challenges, many of which are presented here. Developing vaccines to combat current and future pathogens will require us to overcome those challenges and recent developments in genomic technologies may provide the solutions that we need.CC BY · PubMed Central

Figure 2 The use of vaccinomics in new vaccine development. A wide array of genomic tools and techniques are available for researchers to study various aspects of pathogen biology and host physiology and immune response. Vaccinomics and similar approaches represent toolboxes that contain a specific assortment of laboratory assays, statistical analysis routines, bioinformatic methods, and computational models that can be used to generate an appropriate dataset and extract biologically meaningful results from the data. GWAS, genome wide association study; bnAbs, broadly neutralizing antibodies.CC BY · PubMed Central

Figure 3 Contribution of genomics to vaccine development stages. The results generated by genomic approaches inform each stage of vaccine development. Initial genomics work plays a critical role in discovering new vaccine targets. This is followed by the characterization of these targets in terms of their ability to generate protective immune responses. Validation of the findings in genetically diverse populations is aided by information gained through genomics approaches. Finally, application of the findings assists in the design and completion of phase I–IV clinical trials.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Multi-omics approaches to disease
Hasin, Y., Seldin, M., & Lusis, A. (2017) · Genome Biology · doi:10.1186/s13059-017-1215-1 · Cited by 2,953
InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation
Breuer, K., Foroushani, A. B. K., Laird, M. R., Chen, C. C. L., Sribnaia, A., Lo, R., Winsor, G. L., Hancock, R. E. W., Brinkman, F. S. L., & Lynn, D. J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1147 · Cited by 1,253
MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions
Catalanotto, C., Cogoni, C., & Zardo, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101712 · Cited by 1,238
Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry
Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E., & Engelhard, V. H. (1992) · Science · doi:10.1126/science.1546328 · Cited by 1,198
Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans
Querec, T. D., Akondy, R. S., Lee, E. K., Cao, W., Nakaya, H. I., Teuwen, D. E., Pirani, A. M., Gernert, K. M., Deng, J., Marzolf, B., et al. (2008) · Nature Immunology · doi:10.1038/ni.1688 · Cited by 1,123
Variation in the Human Immune System Is Largely Driven by Non-Heritable Influences
Brodin, P., Jojic, V., Gao, T., Bhattacharya, S., Angel, C. J. L., Furman, D., Shen-Orr, S., Dekker, C. L., Swan, G. E., Butte, A. J., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.020 · Cited by 1,065
Centers for Disease Control and Prevention (CDC)
García-Basteiro, A. L. (2011) · Encyclopedia of Disaster Relief · doi:10.4135/9781412994064.n25 · Cited by 1,021
ImmPort, toward repurposing of open access immunological assay data for translational and clinical research
Bhattacharya, S., Dunn, P. J., Thomas, C. G., Smith, B., Schaefer, H., Chen, J., Hu, Z., Zalocusky, K. A., Shankar, R., Shen-Orr, S. S., et al. (2018) · Scientific Data · doi:10.1038/sdata.2018.15 · Cited by 788
Molecular signatures of antibody responses derived from a systems biology study of five human vaccines
Li, S., Rouphael, N., Duraisingham, S., Romero‐Steiner, S., Presnell, S., Davis, C. W., Schmidt, D. S., Johnson, S. E., Milton, A., Rajam, G., et al. (2013) · Nature Immunology · doi:10.1038/ni.2789 · Cited by 772
Adaptive evolution of highly mutable loci in pathogenic bacteria
Moxon, E. R., Rainey, P. B., Nowak, M. A., & Lenski, R. E. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00005-1 · Cited by 755

Show all 222 references

Sorted by citations

mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
mRNA vaccines in disease prevention and treatment
Zhang, G., Tang, T., Chen, Y., Huang, X., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01579-1 · Cited by 273
Biomaterial-assisted biotherapy: A brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy
Han, X., Alu, A., Liu, H., Shi, Y., Wei, X., Cai, L., & Wei, Y. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.01.011 · Cited by 165
Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
Lee, J., Woodruff, M. C., Kim, E. H., & Nam, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00999-x · Cited by 141
Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19
Vahedifard, F., & Chakravarthy, K. V. (2021) · Emergent Materials · doi:10.1007/s42247-021-00168-8 · Cited by 129
Viral hepatitis update: Progress and perspectives
Pisano, M. B., Giadans, C. G., Flichman, D., Re, V. E., Preciado, M. V., & Valva, P. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i26.4018 · Cited by 118
Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review
Asadi, K., & Gholami, A. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.04.005 · Cited by 98
mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases
Le, T., Sun, C., Chang, J., Zhang, G., & Yin, X. (2022) · Viruses · doi:10.3390/v14020401 · Cited by 99
Recent Review on Biological Barriers and Host–Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies
Deshmukh, R., Sethi, P., Singh, B., Shiekmydeen, J., Salave, S., Patel, R. J., Ali, N., Rashid, S., Elossaily, G. M., & Kumar, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081076 · Cited by 60
Vaccinomics: a future avenue for vaccine development against emerging pathogens
de la Fuente, J., & Contreras, M. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1987222 · Cited by 48
Vaccines and Antivirals: Grand Challenges and Great Opportunities
Andreï, G. (2021) · Frontiers in Virology · doi:10.3389/fviro.2021.666548 · Cited by 48
Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern
Saha, A., Roy, S. G., Dwivedi, R., Tripathi, P., Kumar, K., Nambiar, S. M., & Pathak, R. (2025) · Vaccines · doi:10.3390/vaccines13040424 · Cited by 47
Prophylactic and therapeutic vaccine development: advancements and challenges
Weerarathna, I. N., Doelakeh, E. S., Kiwanuka, L., Kumar, P., & Arora, S. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00222-x · Cited by 47
Systems immunology analysis of human immune organoids identifies host-specific correlates of protection to different influenza vaccines
Wagoner, Z. W., Yates, T. B., Hernandez‐Davies, J. E., Sureshchandra, S., Joloya, E. M., Jain, A., de Assis, R., Kastenschmidt, J. M., Sorn, A. M., Mitul, M. T., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.01.014 · Cited by 30
A Structural View at Vaccine Development against M. tuberculosis
Romanò, M., Squeglia, F., Kramarska, E., Barra, G., Choi, H., Kim, H., Ruggiero, A., & Berisio, R. (2023) · Cells · doi:10.3390/cells12020317 · Cited by 27
Nonclinical safety evaluation of a novel ionizable lipid for mRNA delivery
Broudic, K., Amberg, A., Schaefer, M. K., Spirkl, H.-P., Bernard, M., & Désert, P. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116143 · Cited by 25
Principles in Immunology for the Design and Development of Vaccines
Meyer, C. U., & Zepp, F. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1884-4_2 · Cited by 23
Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems
Li, J., Zhang, Y., Yang, Y., & Sun, T. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00276 · Cited by 24
Advances in Nanotechnology Research in Food Production, Nutrition, and Health
Han, K., Yang, H., Fan, D., & Deng, J. (2025) · Nutrients · doi:10.3390/nu17152443 · Cited by 24
Building a Better Silver Bullet: Current Status and Perspectives of Non‐Viral Vectors for mRNA Vaccines
Gu, J., Xu, Z., Liu, Q., Tang, S., Zhang, W., Xie, S., Chen, X., Chen, J., Yong, K., Yang, C., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302409 · Cited by 20
Immunoinformatics-based multi-epitope containing fused polypeptide vaccine design against visceral leishmaniasis with high immunogenicity and TLR binding
Kumar, P., Kumar, P., Shrivastava, A., Dar, M. A., Lokhande, K. B., Singh, N., Singh, A., Ravichandiran, V., & Mandal, D. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127567 · Cited by 17
Nano-Carriers of COVID-19 Vaccines: The Main Pillars of Efficacy
Constantin, C., Pisani, A., Bardi, G., & Neagu, M. T. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0250 · Cited by 15
Therapeutic Potentials of Immunometabolomic Modulations Induced by Tuberculosis Vaccination
Rawat, B. S., Kumar, D., Soni, V., & Rosenn, E. H. (2022) · Vaccines · doi:10.3390/vaccines10122127 · Cited by 15
Quantum vaccinomics platforms to advance in vaccinology
de la Fuente, J., & Contreras, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172734 · Cited by 14
How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika
Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Jette, C. A., & Björkman, P. J. (2021) · Viruses · doi:10.3390/v13102106 · Cited by 12
Emerging technologies and innovative approaches to combat antimicrobial resistance: A narrative review of next-generation therapeutic strategies
Lucero‐Prisno, D. E., Okesanya, O. J., Agboola, A. O., Adebayo, U. O., Adigun, O. A., Ahmed, M. M., Olaleke, N. O., Oso, T. A., Tan, M. I. R. S., Ogaya, J. B., et al. (2025) · Next Bioengineering · doi:10.1016/j.nxbio.2025.100003 · Cited by 17
Advancements in viral vaccine development: from traditional to modern approaches
Kumar, A., Ahmad, F., Sah, B. K., Aljabali, A. A. A., Mishra, Y., & Mishra, V. K. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003203 · Cited by 14
Graph-theoretical formulation of the generalized epitope-based vaccine design problem
Dorigatti, E., & Schubert, B. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008237 · Cited by 13
Constructing Physiological Defense Systems against Infectious Disease with Metal–Organic Frameworks: A Review
Mishra, N., Quon, A. S., Nguyen, A., Papazyan, E. K., Hao, Y., & Liu, Y. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00391 · Cited by 13
Virus-like particles in poultry disease: an approach to effective and safe vaccination
Raji, A. A., Dastjerdi, P. Z., & Omar, A. R. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1405605 · Cited by 12
Technological breakthroughs and advancements in the application of mRNA vaccines: a comprehensive exploration and future prospects
Wei, Z., Zhang, S., Wang, X., Xue, Y., Dang, S., & Zhai, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524317 · Cited by 16
RNA Vaccines: Yeast as a Novel Antigen Vehicle
Silva, A. J. D., de Sousa, M. M. G., de Macêdo, L. S., Franca-Neto, P. L., de Moura, I. A., Espinoza, B. C. F., Invenção, M. D. C. V., de Pinho, S. S., da Gama, M. A. T. M., & de Freitas, A. C. (2023) · Vaccines · doi:10.3390/vaccines11081334 · Cited by 12
The Nature of the Problem of Immunity and its SolutionPreprint
Ola, P. (2022) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/zmqsg · Cited by 11
Vaccinomics: A scoping review
Dudley, M. Z., Gerber, J. E., Ni, H. B., Blunt, M., Holroyd, T. A., Carleton, B., Poland, G. A., & Salmon, D. A. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.009 · Cited by 10
Self-citation
Recent Global Trends in Vaccinology, Advances and Challenges
Aqib, A. I., Anjum, A. A., Islam, M. A., Murtaza, A., & Rehman, A. U. (2023) · Vaccines · doi:10.3390/vaccines11030520 · Cited by 10
Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine
Nicoli, F., Mantelli, B., Gallerani, E., Telatin, V., Squarzon, L., Masiero, S., Gavioli, R., Palù, G., Barzon, L., & Caputo, A. (2022) · npj Vaccines · doi:10.1038/s41541-022-00458-0 · Cited by 10
Revisiting the dimensions of universal vaccine with special focus on COVID-19: Efficacy versus methods of designing
Jaishwal, P., Jha, K., & Singh, S. P. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134012 · Cited by 10
Methods integrating innate and adaptive immune responses in human in vitro immunization assays
Bowley, T. Y., Lenz, K. D., Shanker, A., & Kubicek-Sutherland, J. Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1584852 · Cited by 8
Pharmacogenomics and Vaccine Development
Poland, G. A., Ovsyannikova, I. G., & Kennedy, R. B. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2288 · Cited by 8
Self-citation
Exploring the genetic diversity of Edwardsiella ictaluri in Vietnamese striped catfish (Pangasianodon hypophthalmus) farms over a 20-year period
Payne, C. J., Grace, K., Phuong, V. H., Phước, N. N., Dung, T. T., Phước, L. H., & Crumlish, M. (2023) · Frontiers in Marine Science · doi:10.3389/fmars.2023.1270968 · Cited by 7
In Silico design of a multi-epitope vaccine for Human Parechovirus: Integrating immunoinformatics and computational techniques
Sarker, A., Rahman, M. M., Khatun, C., Barai, C., Roy, N., Aziz, M. A., Faruqe, M. O., & Hossain, M. T. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302120 · Cited by 7
Retracted
Precise Therapy Using the Selective Endogenous Encapsidation for Cellular Delivery Vector System
Tatarūnas, V., Čiapienė, I., & Giedraitienė, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020292 · Cited by 7
Biodegradable nanoplatforms for antigen delivery: part I – state of the art review of polymeric nanoparticles for cancer immunotherapy
Vega, E., Burgos, J. M., Souto, E. B., García, M. L., Pujol, M., & Sánchez‐López, E. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2400293 · Cited by 6
Advancing novel veterinary vaccines: From comprehensive antigen and adjuvant design to preparation process optimization
Zhang, M., Wang, C., Pan, J., Cui, H., & Zhao, X. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113784 · Cited by 7
Vaccine Development Through Reverse Vaccinology Using Artificial Intelligence and Machine Learning Approach
Bhakta, S., Choudhury, S., Paul, J., & Bhattacharya, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85844-1.00006-4 · Cited by 6
Early B cell transcriptomic markers of measles-specific humoral immunity following a 3rd dose of MMR vaccine
Haralambieva, I. H., Chen, J., Quach, H. Q., Ratishvili, T., Warner, N. D., Ovsyannikova, I. G., Poland, G. A., & Kennedy, R. B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1358477 · Cited by 6
Self-citation
Movement disorders, cerebral palsy and vaccination
Libá, Z., Kraus, J., Necas, T., Necas, J., Klugar, M., & Kršek, P. (2021) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2021.12.006 · Cited by 5
3D printing technologies forin vitrovaccine testing platforms and vaccine delivery systems against infectious diseases
Choi, J. Y., Mahadik, B. P., & Fisher, J. P. (2021) · Essays in Biochemistry · doi:10.1042/ebc20200105 · Cited by 5
Exploring natural components in vaccine delivery systems: Types, routes of administration, in-vitro and in-vivo quantification techniques
Sugandhi, V. V., Gadhave, D. G., Khot, S. V., Jadhav, K., Patel, D., Thapa, R., Verma, R. K., Rojekar, S. V., Patil, N. G., Jha, S. K., et al. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106960 · Cited by 4
Applied immunoinformatics in modern vaccine design: a comprehensive review of available computational tools
Miles, S., Mourglia‐Ettlin, G., & Chabalgoity, J. A. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128392 · Cited by 4
A Commentary on Multi-omics Data Integration in Systems Vaccinology
Shannon, C. P., Lee, A. H., Tebbutt, S. J., & Singh, A. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168522 · Cited by 4
Vaccine Based Approaches for the Prevention and Treatment of Neurological Disease
Aderinto, N., Abraham, I. C., Olatunji, G. D., Kokori, E., Ashinze, P. T., Babawale, E. A., Alabi, B. O., Opeyemi, O. D., Babalola, A. E., Ayoola, O. I., et al. (2025) · Current Treatment Options in Neurology · doi:10.1007/s11940-025-00827-9 · Cited by 5
Myopericarditis after COVID-19 vaccination: unexpected but not unprecedented
Ryan, M., & Montgomery, J. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00091-1 · Cited by 4
Polyvalent immunization elicits a synergistic broadly neutralizing immune response to hypervariable region 1 variants of hepatitis C virus
Mosa, A. I., Campo, D. S., Khudyakov, Y. E., Haidar, M. A., Gehring, A. J., Zahoor, M. A., Ball, J. K., Urbanowicz, R. A., & Feld, J. J. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220294120 · Cited by 4
Application of gold nanoparticles in vaccine development
Farfán-Castro, S., García-Soto, M. J., Aguilar‐Aguilar, A., González‐Ortega, O., & Rosales‐Mendoza, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19061-2.00003-1 · Cited by 4
Immunoinformatics-guided vaccine design: A review with case study on Marburg virus
Rao, D. F., Patel, S., & Pandya, H. A. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152572 · Cited by 3
Prevention as a Pillar of Communicable Disease Control: Strategies for Equity, Surveillance, and One Health Integration
Genovese, G., Rizzo, C. E., Bartucciotto, L., Calderone, S. M., Loddo, F., Leonforte, F., Mistretta, A., Squeri, R., & Genovese, C. (2026) · Epidemiologia · doi:10.3390/epidemiologia7010019 · Cited by 4
Ex vivo observation of Pythium insidiosum -antigen treated neutrophils on three Pythium insidiosum strains isolated from vascular pythiosis patients
Medhasi, S., Sriwarom, A., Permpalung, N., Torvorapanit, P., Plongla, R., Chindamporn, A., & Worasilchai, N. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2304372 · Cited by 3
Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
Domnich, A., Orsi, A., Lai, P. L., Massaro, E., Trombetta, C.-S., Pastorino, J., Roihl, C., Pianta, M., Icardi, G., & Panatto, D. (2025) · Medicina · doi:10.3390/medicina61010067 · Cited by 3
The mental health implication of mpox: Enhancing care with genetic insights
Ejiohuo, O. (2025) · Journal of Public Health in Africa · doi:10.4102/jphia.v16i1.786 · Cited by 3
Major locus on ECA18 influences effectiveness of GonaCon vaccine in feral horses
Thompson, M. A., McCann, B. E., Simmons, R. B., & Rhen, T. (2022) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2022.103779 · Cited by 3
Heightened innate immune state induced by viral vector leads to enhanced response to challenge and prolongs malaria vaccine protection
Gbédandé, K., Ibitokou, S. A., Endrino, M. J., Yap, G. S., Brown, M. G., & Stephens, R. (2024) · iScience · doi:10.1016/j.isci.2024.111468 · Cited by 3
A Preliminary Investigation on a Commercial Ovine Pasteurellosis Vaccine Using Clinical and Pathological Endpoints
Asfaw, M., Senbit, M., Yesuf, M., Fenta, M. D., Birhan, G., Abat, A. S., & Ibrahim, S. M. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s365745 · Cited by 3
Genetic origins of microbial virulence
Chatterjee, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-31554-1.00010-8 · Cited by 3
Mandatory Childhood Vaccinations in Poland—The Art of Preventing the PreventablePreprint
Kamińska, A., & Plata‐Nazar, K. (2023) · Preprints.org · doi:10.20944/preprints202311.0261.v1 · Cited by 2
Machine learning (ML) and deep learning (DL) in vaccine target selection, design, development and characterization
Bhattacharya, M., Chatterjee, S., Das, A., Lee, S., & Chakraborty, C. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.128051 · Cited by 2
Engineering cationic nanovaccines to enable precision immunotherapy in infectious diseases and cancer
Lee, S., Kim, J., Kim, B., Kim, B.-S., Shin, J., Choi, J., Kim, M., Seo, Y. H., Kim, B. H., Lim, K. S., et al. (2026) · Discover Applied Sciences · doi:10.1007/s42452-025-08209-1 · Cited by 2
Nanovaccines in cancer immunoprevention and immunotherapy: Current insights and future directions
Uti, D. E., Alum, E. U., & Ugwu, O. P.-C. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101166 · Cited by 2
Enhancing mRNA therapeutics production: A platform technology approach through IVT modeling insights
Ahmed, M., Nair, A., Middleton, J., Loveday, K. A., Brown, S., Kis, Z., & Cordiner, J. (2026) · Results in Engineering · doi:10.1016/j.rineng.2026.110088 · Cited by 2
A Narrative Review on the Promising Potential of Graphene in Vaccine Design: Evaluating the Benefits and Drawbacks of Carbon Nanoplates in Nanovaccine Production
Zare‐Zardini, H., Saberian, E., Jenča, A., Jenča, A., Petrášová, A., & Jenčová, J. (2024) · Vaccines · doi:10.3390/vaccines12060660 · Cited by 2
Towards precision epitopes based vaccine against Enterococcus faecalis by integrating vaccinomics, reverse vaccinology and biophysics approaches
Ullah, A., Azam, S., Ahmad, S., Khan, I., Alammari, D. M., Abassi, S. W., Wei, D., Alshabrmi, F. M., Aljasir, M. A., & Alatawi, E. A. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102082 · Cited by 2
Why not the ‘marker’ or DIVA vaccines for the control of emerging infectious diseases of humans?
Singh, A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.01.069 · Cited by 2
AI-Assisted Vaccine Design and Development in Immunological Disorders
Tavare, N., Singh, R., & Barage, S. H. (2025) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3693-9725-1.ch006 · Cited by 1
Harnessing immunoinformatics for the rational design of mRNA vaccines against the emerging Junin virus
Oladipo, E. K., Irewolede, B. A., Aderibigbe, K. A., Hammed, O. S., Jegede, A. J., Opeyemi, O. H., Adaeze, C. J., Adedotun, O. J., Adebola, A. M., Dorcas, A. O., et al. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00587-7 · Cited by 1
mRNA vaccines for viral diseases: mechanism, advances, and future perspective
Chakraborty, B., & Singh, T. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11856-1 · Cited by 1
Role of nanotechnology in diagnosis and disease control with a focus on COVID-19 and future perspectives
Rashid, M. H. A., Saha, D., & Mandal, S. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90750-7.00004-1 · Cited by 1
Individual expression and processing of hepatitis C virus E1/E2 epitopes-based DNA vaccine candidate in healthy humans’ peripheral blood mononuclear cells
Nadeem, R., Maghraby, A. S., Abd‐Elshafy, D. N., Barakat, A., & Bahgat, M. M. (2023) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2023.12.1.47 · Cited by 1
Personalized vaccinology
Garse, S., Dokhale, S., Bhandari, G. K., Kapadiya, V., Prabhakar, K., & Devarajan, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15526-0.00002-0 · Cited by 1
Gut microbiota modulate immune responses to orally and parenterally administered rotavirus in mice
Shi, Z., Moon, S.-S., Zou, J., Wang, Y., Bhatnagar, N., Ngo, V. L., Wang, X., Wang, H., Bessey, T. K., Hull, J. J., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01126-9 · Cited by 1
Brief Introduction of Measles Virus and Its Therapeutic Strategies
Nascimento, I. J. D. S., Santos-Júnior, P. F. D. S., & da Silva‐Júnior, E. F. (2021) · Springer eBooks · doi:10.1007/978-3-030-71165-8_23 · Cited by 1
The Art of Oncoimmunovaccinomics
Ikrar, T., & Anurogo, D. (2021) · World Journal of Vaccines · doi:10.4236/wjv.2021.114007 · Cited by 1
Voluntariness or legal obligation? An ethical analysis of two instruments for fairer global access to COVID-19 vaccines
Voit, K., Timmermann, C., Orzechowski, M., & Steger, F. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.995683 · Cited by 1
The Nature of the Problem of Immunity and its SolutionPreprint
Ola, P. (2022) · doi:10.22541/au.165926450.03622785/v1 · Cited by 1
Nanotechnology and Vaccine Development
Jetha, K. L., Bharadia, P. D., & Patel, M. P. (2024) · doi:10.1002/9781394175482.ch3 · Cited by 1
Charting targeted courses for vaccination
(2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01366-z · Cited by 1
Develop a durable, memory-driven, CspZ-targeting Lyme disease vaccine by rationale adjuvant selectionPreprint
McCarty, M., Hernández, S. A., Malfetano, J., Leao, A. C., Villar, M. J., Yang, X., Chen, Y.-L., Lee, J., Liu, Z., Strych, U., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.08.698480 · Cited by 1
Expected and Unexpected Effects of Vaccination
Martinón‐Torres, F. (2021) · Springer eBooks · doi:10.1007/978-3-030-77173-7_1
Covid-19: Estratégias gerais nas instituições de ensino
Troca, R. S., Mundim, F. G. L., & Salomé, G. M. (2022) · doi:10.22533/at.ed.938222511
Персоніфікований підхід у вакцинопрофілактиці в умовах воєнного та повоєнного часу
Смілянська, М. В., Волянський, А., Мороз, М., & Звєрєва, Н. (2024) · InterConf · doi:10.51582/interconf.19-20.02.2024.045
Anais Eletrônicos do XX Congresso de Iniciação Científica da Univás - 2023
Mendonça, A. R. D. A., Lopes, A. N., Silva, A. M. F., Salles, A. C., Carlos, B. L., Pereira, D. H., de Castro, F. E., dos Santos, M. A., Nogueira, J. P. D. F., Neto, J. D. D. S., et al. (2023) · doi:10.54665/9786585924016
Systems Biology in the Field of Vaccine Development
Okay, S. (2024) · RNA technologies · doi:10.1007/978-3-031-62178-9_12
Revolutionizing Healthcare: Unleashing the Potential of Immunotherapies to Strengthen the Body’s Immune Defense Against Antibiotic-Resistant Pathogen
Patil, A., Nagulwar, V. P., Yadav, S. K., Tabassum, F., & Gautam, S. S. (2024) · Springer eBooks · doi:10.1007/978-981-97-5272-0_7
Immunological and Immunogenetic Aspects of Vaccination against Measles
Фомичев, В. И., Михайловна, Х. С., & Vilnits, A. A. (2025) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2025-24-3-114-122
The Future of Vaccine IP Right
Raghuwanshi, V., Jain, S. K., & Soni, S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815274769125010010
The State of Public Opinion on the Immunoprophylaxis of Infectious Diseases
Solov’yov, D. V., Glinenko, V. M., Sapozhnikova, E. V., Smirnova, O. A., Korabelnikova, M. I., Васильевич, Д. Д., Vlasenko, N. V., Panasyuk, Y. V., Nikitina, G. Y., & Кузин, С. Н. (2025) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2025-24-4-42-51
Effect of Particle Synthesis Method on Protein Release and Stability
Sanchez, D., & Narasimhan, B. (2025) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.35685
Vaccine Clinical Trials
Madhavrao, C., Bai, K. M., Chenchula, S., & SHARMA, S. K. (2025) · Introduction to Basics of Pharmacology and Toxicology · doi:10.1007/978-981-95-1920-0_19
An integrated immunoinformatic approach to design a novel multiepitope chimeric vaccine against Mycoplasma phocimorsus as a causal agent of bloodstream infections
Yu, R., Hasan, A., Ibrahim, M. K., Alonazi, W. B., & Li, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1719398
Designing a multi-epitope vaccine to harness computational immunology for next-generation tuberculosis control
Olatunde, S. K., Oyedele, A. O., Alli, Y. A., Oladipo, E. K., Ajisafe, H. M., & Abiodun, C. S. (2026) · Next research. · doi:10.1016/j.nexres.2026.101398
Undergraduate interest in vaccines: insights from the “Adopt a Bacterium” active learning methodology in the post-COVID-19 Period
Baroni, L. N., Picinin, N. G., Nastaro, C. D., Marana, S. R., Moreno, A. C. R., & Ferreira, R. D. C. C. (2026) · Journal of Biological Education · doi:10.1080/00219266.2026.2628790

Authors: Kennedy, R. B., Ovsyannikova, I. G., Palese, P., & Poland, G. A.
Affiliations: Mayo Clinic (US)
Icahn School of Medicine at Mount Sinai (US)
Corresponding author: Kennedy, Richard B.
ORCID: Kennedy, Richard B.
Ovsyannikova, Inna G.
Palese, Peter
Poland, Gregory A.
Venue: Frontiers in Immunology
Publisher: Frontiers Media SA
Published: 2020-06-25
Volume: 11
Pages: 1181-1181
ISSN: 1664-3224 (ISSN-L)
DOI: 10.3389/fimmu.2020.01181
PMC: PMC7329983
OpenAlex: W3033639218
Cited by: 113
References: 222
Citations by year: 2026: 22 · 2025: 24 · 2024: 21 · 2023: 16 · 2022: 12 · 2021: 17 · 2020: 1
FWCI: 1.10
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Frontiers in Immunology (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Institutes of Health (R01AI033144, R01AI121054, R01AI127365, R01AI132348, R01AI138965, R37AI048793, U01AI089859)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords: vaccine development, vaccinomics, host genetic variation, host immune response, omics technologies, bioinformatics, infectious disease prevention, emerging pathogens
MeSH terms: Vaccinology, Animals, Communicable Disease Control, Humans, Vaccines, Computational Biology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Current Challenges in Vaccinology

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks